In Depth 10 Jan 2024 The biggest private biotech investments in December 2023 The companies Tome Biosciences, Bicara Therapeutics, and Seismic Therapeutic bagged the biggest biotech investments in December 2023. Around the world, food, immunology, oncology, central nervous system (CNS), and biofermentation players attracted the biggest funding rounds overall. Although December is generally a quiet time for biotech fundraising, there were still some big rounds raised in the […] January 10, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Dec 2023 Five companies racing to bring their NASH treatments toward the finish line NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), where fat builds up on the liver, potentially leading to liver damage or cirrhosis. With no U.S. Food and Drug Administration (FDA)-approved treatments for the disease, many NASH companies are currently attempting to bring their candidates toward approval. In this article, we take a […] December 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 8 Dec 2023 Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news. December 8, 2023 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Dec 2023 The biggest private biotech investments in November 2023 The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […] December 7, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2023 A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […] December 6, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Nov 2023 Five companies shaping Texas’ growing biotech hubs Thanks to the U.S. government’s ambitious plans to advance American biotech and biomanufacturing, Texas’ life sciences hubs, particularly in Dallas and Houston, are now one of many in the country that are currently thriving. In this article, we take a closer look at several biotech companies in Texas taking advantage of the additional investment in […] November 28, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Nov 2023 Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […] November 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2023 Beyond insulin: six cutting-edge diabetes biotech companies you should know about As we predicted last year, the diabetes market is booming, particularly after the incredible success of new diabetes drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. There are now several diabetes biotech companies that are garnering attention, all with their own innovative solutions to tackling both type 1 and type 2 diabetes. The prevalence […] November 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 16 Nov 2023 Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […] November 16, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Nov 2023 10 biotech companies leading innovation in the Asia-Pacific region Asia-Pacific is now establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region. The life sciences industry is thriving, and there has been a shift in the region from predominantly producing generics to developing innovative technologies, with several Asia-Pacific biotech companies leading […] November 14, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […] November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Nov 2023 The biggest private biotech investments in October 2023 The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […] November 6, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email